Exhibit 10.32
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
LICENSE AND ASSIGNMENT AGREEMENT
by and between
SEPRACOR INC.
and
▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇
September 30, 1999
This document is the confidential information of both parties hereto.
It should be distributed on a need-to-know basis and kept in a secure area.
TABLE OF CONTENTS
ARTICLE 1 - DEFINITIONS......................................................1
ARTICLE 2 - ASSIGNMENT AND LICENSE GRANT.....................................4
ARTICLE 3 - ROYALTIES AND OTHER CONSIDERATION................................5
ARTICLE 4 - ROYALTY PAYMENTS, REPORTS AND RECORDS............................7
ARTICLE 5 - COOPERATION, TECHNOLOGY TRANSFER, AND INVENTIONS.................8
ARTICLE 6 - INFRINGEMENT....................................................11
ARTICLE 7 - CONFIDENTIALITY.................................................11
ARTICLE 8 - TERM............................................................13
ARTICLE 9 - BREACH AND TERMINATION..........................................13
ARTICLE 10 - REPRESENTATIONS,WARRANTIES AND CONVENANTS......................13
ARTICLE 11 - ADVERSE EVENTS.................................................16
ARTICLE 12 - INDEMNIFICATION................................................16
ARTICLE 13 - CHOICE OF LAW..................................................17
ARTICLE 14 - FORCE MAJEURE..................................................17
ARTICLE 15 - NOTICES........................................................18
ARTICLE 16 - WAIVER.........................................................19
ARTICLE 17 - ENTIRE AGREEMENT...............................................19
ARTICLE 18 - ASSIGNMENT.....................................................19
ARTICLE 19 - TITLES.........................................................19
ARTICLE 20 - PUBLICITY......................................................20
ARTICLE 21 - UNENFORCEABLE PROVISIONS.......................................20
ARTICLE 22 - CONSTRUCTION...................................................20
i
ARTICLE 23 - OWNERSHIP......................................................20
ARTICLE 24 - INDEPENDENT CONTRACTORS........................................21
ARTICLE 25 - EXECUTION......................................................21
SCHEDULE 1.15 - RPR PATENT APPLICATIONS
SCHEDULE 2.1 - FORM OF ASSIGNMENT
ii
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
This License and Assignment Agreement is made as of this 30th day of September,
1999 by and between Sepracor Inc., a Delaware corporation having a place of
business at ▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ("Sepracor"), and
▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇, a French corporation having a place of business at ▇▇,
▇▇▇▇▇▇ ▇▇▇▇▇▇▇-▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ ("RPR").
BACKGROUND
WHEREAS, Sepracor is the assignee of U.S. Patent No. 5,786,357 issued July 28,
1998, relating to use of (+) zopiclone (the "Sepracor Patent") and is interested
in developing pharmaceutical products containing (+) zopiclone as an active
ingredient for sale in the United States;
WHEREAS, RPR owns U.S. Patent Application Serial No. [**] filed July 29, 1998,
relating to use of (+) zopiclone (the "RPR Application" as further defined
hereinafter), and certain know-how relating to the use of zopiclone, its
enantiomers and metabolites;
WHEREAS, Patent Interference Number 104,423 (the "Interference") was declared by
the U.S. Patent and Trademark Office ("PTO") between the Sepracor Patent and the
RPR Application;
WHEREAS, on the terms and conditions set forth herein, RPR is willing to assign
the RPR Application to Sepracor and license to Sepracor the exclusive right
under certain RPR know-how to make, have made, use, market, sell, offer for
sale, have sold, and distribute pharmaceutical products containing (+)
zopiclone, in the United States; and
WHEREAS, Sepracor wishes to accept such assignment and license.
NOW, THEREFORE, in consideration of the mutual promises, covenants and
agreements hereinafter set forth, the sufficiency of which is hereby
acknowledged, the parties to this Agreement mutually agree as follows:
ARTICLE 1 - DEFINITIONS
For purposes of this Agreement, the following initially capitalized terms in
this Agreement, whether used in the singular or plural, shall have the following
meanings, unless the context clearly requires otherwise:
1.1 "Affiliate" shall mean, with respect to either party hereto, any
corporation, company, partnership, joint venture or any other entity which
directly or indirectly controls, is controlled by, or is under common
control with such party. For purposes of this definition, "control" shall
mean direct or indirect ownership of at least fifty percent (50%)
outstanding voting securities of the entity.
1
1.2 "Agreement" shall mean this License and Assignment Agreement.
1.3 "Business Day" shall mean a day on which banks are open for business in
both Marlborough, Massachusetts and Philadelphia, Pennsylvania.
1.4 "Compound" shall mean the compound known as (+) zopiclone, also identified
by the chemical name (+) 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-
pyrrolo [3,4b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate or (+)
6-(5-chloropyri-2-dyl)- 5-(4-methylpiperazin-1-yl) carbonyloxy-7-oxo-6,7-
dihydro-5H-pyrrolo [3,4b] pyrazine.
1.5 "Confidential Information" shall mean all RPR Know-How, and all technical
and scientific know-how and information, pre-clinical and clinical trial
results, computer programs, knowledge, technology, means, methods,
processes, practices, formulas, techniques, procedures, designs, drawings,
apparatus, written and oral representations of data, specifications, and
all other scientific, clinical, regulatory, marketing, financial and
commercial information or data, whether communicated in writing, verbally
or electronically, which is provided by one party to the other party in
connection with this Agreement.
1.6 "Control" or "Controlled", when used in connection with intellectual
property rights, shall mean the legal authority or right of a party hereto
to grant a license or sublicense of intellectual property rights to
another party hereto, or to otherwise disclose proprietary or trade secret
information to such other party, without breaching the terms of any
agreement with a Third Party, or misappropriating the proprietary or trade
secret information of a Third Party. Information that is generally known
or available to the public shall not be deemed Controlled by a party
hereto.
1.7 "Effective Date" shall mean, except to the extent necessary to permit the
initial payment by Sepracor set forth Section 3.2.1 , the latest of (a)
the date on which RPR executes this Agreement; (b) the date on which
Sepracor executes this Agreement; (c) if applicable, the next Business Day
following the expiration or earlier termination of any notice and waiting
period under the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Antitrust Improvements Act of 1976, as
amended ("HSR Act"); and (d) the date on which the parties agree that no
filing under the HSR Act is required.
1.8 "Generic Version" shall mean any pharmaceutical product containing
Compound that is introduced in the Territory by a Third Party as a result
of an Abbreviated New Drug Application relying on a New Drug Application
for a Product filed by Sepracor or its Affiliate or Licensee.
1.9 "Improvement" shall mean any enhancement of or improvement to the
formulation, ingredients, preparation, presentation, means of delivery,
dosage, packaging of, manufacture, or any new or expanded therapeutic
indication(s) specifically relating to Compound developed, invented or
acquired by, or coming under the Control of, RPR or
2
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
an Affiliate thereof during the term of this Agreement, including but not
limited to, any patents or patent applications embodying any of the
foregoing.
1.10 "Interference" shall mean Patent Interference Number 104,423.
1.11 "Licensee" shall mean any person, corporation, unincorporated body, or
other entity that is not an Affiliate of Sepracor and to whom Sepracor
grants a license or sublicense of the rights assigned or granted to
Sepracor pursuant to this Agreement.
1.12 "Net Sales" shall mean, with respect to Product, the gross amount invoiced
by Sepracor, its Affiliates and Licensees on all sales of Product (but not
including sales between or among Sepracor, its Affiliates and Licensees)
less (a) [**] (provided that [**] are [**] to the [**] as applicable) [**]
or to [**] including [**] (b) [**] for [**] for [**] or [**], (c) [**] and
[**] and (d) [**] and other [**] with the sale, to the [**] what are [**]
1.13 "Payment Period" shall mean a calendar quarter ending on March 31st, June
30th, September 30th, or December 31st.
1.14 "Product" shall mean any composition which contains Compound as an active
ingredient, including any composition which contains Compound and one or
more other active ingredients.
1.15 "RPR Application" shall mean the patent applications listed in Schedule
1.15, and any and all additions, divisions, continuations,
continuations-in-part, reissues, reexaminations, substitutions,
extensions, patent term extensions and renewals thereof, and patents
issued therefrom.
1.16 "RPR Know-How" shall mean all proprietary, non-public information
specifically relating to Zopiclone Technology, including, without
limitation, processes, techniques, formulas, formulations and formulation
technology, data, methods (including but not limited to analytical
methods), equipment designs, know-how, show-how and trade secrets,
patentable or otherwise, tangible or intangible, that are owned or
Controlled by RPR or an Affiliate thereof as of the date of execution of
this Agreement. RPR Know-How shall include all Chemistry, Manufacturing
and Control ("CMC"), preclinical, and clinical data in the possession of
RPR or its Affiliates relating to Compound, the racemate or the other
enantiomer thereof, or metabolites of any of the foregoing, including
regulatory filings and post-launch European safety dossiers.
1.17 "Regulatory Approval" means, with respect to the Territory, receipt of all
governmental and regulatory registrations and approvals (including, but
not limited to, approvals of all
3
final Product labeling) required for the marketing and sale of Product in
the Territory.
1.18 "Territory" shall mean the United States of America and its territories
and possessions.
1.19 "Third Party" shall mean any person, corporation, unincorporated body, or
other entity other than RPR and its Affiliates and Sepracor and its
Affiliates and Licensees.
1.20 "Zopiclone Technology" shall mean technology specifically related to
Compound, the racemate or the other enantiomer thereof, or metabolites of
any of the foregoing.
ARTICLE 2 - ASSIGNMENT AND LICENSE GRANT
2.1 Within ten (10) Business Days of the Effective Date of this Agreement, RPR
shall assign all right, title and interest to the RPR Application to
Sepracor pursuant to an assignment substantially in the form attached
hereto as Schedule 2.1. Upon execution by RPR, such assignment shall be
transmitted promptly to Sepracor and Sepracor may, at its sole discretion,
attend to filing and recordation thereof with the U.S. Patent and
Trademark Office (PTO).
2.2 RPR grants to Sepracor an exclusive license (exclusive even as to RPR and
its Affiliates, except as provided under Section 2.7) under the RPR
Know-How and Improvements to develop, have developed, make, have made,
use, market, sell, offer for sale, have sold and distribute Product in the
Territory. RPR agrees not to assert any claims for patent infringement in
the Territory based on manufacture, use or sale of Product made, used or
sold by Sepracor, its Affiliates or Licensees during the term of this
Agreement.
2.3 For the avoidance of any doubt, the parties expressly agree that the grant
set forth in Section 2.2 above shall include, but not be limited to, the
right to read, reference, copy, summarize, and use any and all Chemistry,
Manufacturing and Control ("CMC"), preclinical, and clinical data in the
possession of RPR or its Affiliates, and expert reports relating to any of
the foregoing, relating to Compound, the racemate or the other enantiomer
thereof, or metabolites of any of the foregoing, including regulatory
filings and post-launch European safety dossiers, for the purpose of
development and registration of Product in the Territory,
2.4 Sepracor agrees to use commercially reasonable efforts to obtain
Regulatory Approvals for, commercialize and sell Product in the Territory,
consistent with those efforts used for Sepracor's own ethical
pharmaceutical products with similar market potential, all in accordance
with the terms of this Agreement. The parties acknowledge and agree that
all business decisions including, without limitation, decisions relating
to Sepracor's research, development, regulatory strategy, registration,
manufacture, sale, commercialization, design, price, distribution,
marketing and promotion of Products in the Territory, shall be within the
sole discretion of Sepracor. RPR acknowledges that Sepracor is in the
business
4
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
of developing, manufacturing and selling pharmaceutical products and,
subject to the provisions of this Section, nothing in this Agreement shall
be construed as restricting such business or imposing on Sepracor the duty
to market and/or sell and exploit Compound or Product for which royalties
are payable hereunder to the exclusion of, or in preference to, any other
product, or in any way other than in accordance with its normal commercial
practices.
2.5 The rights and licenses granted hereunder shall be sublicensable by
Sepracor subject to the terms and conditions set forth in this Agreement,
provided that Sepracor remains responsible to RPR under this Agreement.
2.6 To the extent necessary, each of RPR and Sepracor shall file within twenty
(20) Business Days after the date of this Agreement with the Federal Trade
Commission and the Antitrust Division of the U.S. Department of Justice,
any notification and report form required of it in the reasonable opinion
of both Parties under the HSR Act with respect to the transactions
contemplated hereby. The parties shall cooperate with one another to the
extent necessary in the preparation of any notification and report form
required to be filed under the HSR Act. Each Party shall be responsible
for its own costs, expenses, and filing fees associated with any filing
under the HSR Act.
2.7 Nothing in this Agreement shall impair or limit RPR's, or its Affiliates'
or sublicensees', right under RPR Know-How and Improvements to make or
have made Product within the Territory for marketing, distribution, sale
or use solely and exclusively outside the Territory.
2.8 Notwithstanding anything else to the contrary in this Agreement, neither
the assignment of Section 2.1, the license of Section 2.2, nor beneficial
ownership of any of the assigned assets or licensed rights hereunder shall
be transferred to Sepracor prior to the Effective Date of this Agreement.
ARTICLE 3 - ROYALTIES AND OTHER CONSIDERATION
3.1 In partial consideration of the assignment of the RPR Application and the
rights and licenses granted in Sections 2.2 and 2.3:
3.1.1 Sepracor shall pay to RPR a royalty on the Net Sales of Product in
the Territory ("Royalties") as follows:
[**] of Net Sales of all Product in the Territory.
5
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
3.1.2 Section 3.1.1 notwithstanding, if Product is sold by a Licensee, in
connection with such sales Sepracor shall pay to RPR the amount set
forth in Section 3.1.1 using net sales as reported to Sepracor by
the Licensee as Net Sales by Sepracor.
3.1.3 Section 3.1.1 notwithstanding, if Product is sold containing both
Compound and one or more other substances as active ingredients
excluding (-)-zopiclone ("Combination Product"), the Royalty for
such Combination Product shall be [**] of Net Sales of all
Combination Product in the Territory.
3.1.4 Royalties shall be payable until the introduction in the Territory
of a Generic Version of Product by a Third Party without approval or
consent of Sepracor or any Affiliate or Licensee thereof.
3.2 In partial consideration of the assignment of the RPR Application and the
rights and licenses granted in Sections 2.2 and 2.3, Sepracor shall pay to
RPR an up-front fee and milestone payments as follows:
3.2.1 [**] within [**] Business Days of the execution of this Agreement,
provided, however, such amount shall be refunded to Sepracor if the
assignment and licenses set forth in Article 2 are not made e
ffective under this Agreement ;
3.2.2 [**] within [**] Business Days after initiation by Sepracor or its
Affiliates or Licensee of Phase III clinical studies of Product;
3.2.3 [**] within [**] Business Days after filing of an NDA for Product by
Sepracor or its Affiliates or Licensee; and
3.2.4 [**] within [**] Business Days after approval of Sepracor's or its
Affiliate's or Licensee's NDA for Product; provided, however, that
if the rights granted to Sepracor under Sections 2.2 and 2.3 hereof
enable Sepracor to gain approval of said NDA without conducting any
carcinogenicity trials, any one-year safety study in humans, and
obtaining chronic exposure safety data in humans that, in any such
case, are required by the United States Food and Drug Administration
("FDA") to be completed or obtained prior to FDA approval of the
Product, then the payment shall be [**]
6
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
ARTICLE 4 - ROYALTY PAYMENTS, REPORTS AND RECORDS
4.1 Sepracor shall deliver to RPR within [**] days following the end of each
Payment Period, beginning with the first Payment Period, a written report
(the "Royalty Statement") describing in sufficient detail, for the
applicable Payment Period:
(a) the calculation of Net Sales from the gross revenues for all
Products; and
(b) the total Royalties due for the Payment Period.
4.2 Each Royalty Statement for a Payment Period required by Section 4.1 above
shall be accompanied by full payment to RPR of the payments due to RPR
under Articles 3 and 4.
4.3 With regard to any payments due to RPR, the following shall apply:
(a) All payments to RPR pursuant to this Agreement shall be made by wire
transfer and in accordance with written instructions to be provided
by RPR in accordance with Article 15. All such payments shall be
made in United States Dollars ("Dollars").
(b) Whenever any payment hereunder shall be stated to be due on a day
which is not a Business Day, such payment shall be made on the
immediately succeeding Business Day.
(c) Payments hereunder shall be considered to be made as of the day on
which they are received in RPR's designated bank account.
(d) All payments due to RPR hereunder but not paid by Sepracor on the
due date thereof shall bear interest at the rate which is the lesser
of: (i) LIBOR plus two percent (2%) per annum; and (ii) the maximum
lawful interest rate permitted under applicable law. Such interest
shall accrue on the balance of unpaid amounts from time to time
outstanding from the date on which portions of such amounts become
due and owing until payment thereof in full.
4.4 Any income or other taxes which Sepracor is required by law to pay or
withhold on behalf of RPR with respect to Royalties, and any interest
thereon, payable to RPR under this Agreement shall be deducted from the
amount of such Royalties and interest due, and paid or withheld, as
appropriate, by Sepracor on behalf of RPR. In such event, Sepracor shall
timely pay or remit all amounts so withheld to the appropriate taxing
authorities on RPR's behalf and promptly provide RPR with a written tax
receipt for such amount issued by such taxing authority. Sepracor shall
obtain for RPR, at its request, any other documentation, receipt or
certificate necessary or desirable for RPR to apply for and/or
7
receive any corresponding tax refund or credit under any applicable tax
law or treaty. Any such tax required to be paid or withheld shall be an
expense of and borne solely by RPR. The foregoing sentences
notwithstanding, the parties hereto will reasonably cooperate in
completing and filing documents required under the provisions of any
applicable tax laws or under any other applicable law, in order to enable
Sepracor to make such payments to RPR without any deduction or
withholding.
4.5 Sepracor shall keep and maintain, and shall cause its Affiliates to keep
and maintain, complete and accurate records and books of account in
accordance with Generally Accepted Accounting Principles in sufficient
detail and form so as to enable amounts payable under Articles 3 and 4 to
be determined, including but not limited to, true and accurate records of
sales of Products and calculations of Net Sales and Royalties. RPR shall
have the right, at its own cost and expense, to audit the records of
Sepracor and its Affiliates using a nationally recognized firm of
independent certified accountants reasonably acceptable to Sepracor. Such
accountants will have access on reasonable notice to Sepracor and its
Affiliates' records during reasonable business hours for the sole purpose
of verifying the Royalties payable as provided in this Agreement for the
three preceding years provided, however, that if there is a good faith
dispute between the parties continuing at the end of any such three (3)
year period with respect to such books or records, then the time period
hereunder to maintain such books and records under dispute and for any
subsequent period shall be extended until such time as the dispute is
finally resolved. This right may not be exercised more than once in any
calendar year, and once a calendar year is audited it may not be
reaudited, provided that if there is a dispute as to any audited year,
such year and any subsequent year may be reaudited until such time as the
dispute is resolved. Said accountant shall disclose to RPR only
information relating solely to the accuracy of the Royalty Statements
provided to RPR and the payments made to RPR under this Agreement. The
provisions of this Section 4.5 shall survive the expiration or sooner
termination of this Agreement.
4.6 Any underpayment determined as a result of an audit conducted under this
Article shall be paid to RPR within twenty-five (25) days after the date
on which the accountant conducting the audit issues a written report to
RPR and Sepracor containing the results of the audit. If any underpayment
by Sepracor is greater than ten percent (10%) of the amount previously
paid to RPR for the relevant Payment Period, the costs and expenses of the
audit shall be paid for by Sepracor. Any overpayment shall be credited to
the next payment to RPR due hereunder.
ARTICLE 5 - COOPERATION, TECHNOLOGY TRANSFER, AND INVENTIONS
5.1 RPR shall use good faith reasonable efforts to consult and cooperate with
Sepracor with respect to the filing of any patent applications for
Improvements and the maintenance of patents issued thereon including,
without limitation, by executing and obtaining from employees assignments
and other documents reasonably required in connection therewith,
8
provided, however, that RPR may refuse to execute such documents if RPR
makes a good faith reasonable determination that any such document is
factually or legally incorrect.
5.2 The parties agree to use good faith reasonable efforts to cooperate in
order to avoid loss of any rights which may otherwise be available to the
parties under the U.S. Drug Price Competition and Patent Term Restoration
Act of 1984 and other similar measures. Without limiting the foregoing,
each of Sepracor and RPR agrees to provide the other with reasonable
information and assistance in order to permit the timely filing of an
application for patent term extension within the sixty (60) day period
following NDA approval to market Product in the United States.
5.3 After the Effective Date, RPR shall provide Sepracor full access to the
information referenced in Section 2.3 hereof and shall use good faith
reasonable efforts in fully cooperating with Sepracor in order to enable
Sepracor to obtain Regulatory Approval of Products. At Sepracor's request,
RPR shall disclose to Sepracor in writing, or via mutually acceptable
electronic media, copies or reproductions of all written RPR Know-How
reasonably available to RPR or its Affiliates in order to enable Sepracor
to obtain Regulatory Approval of Products. . In addition, during the term
of this Agreement, RPR shall promptly disclose to Sepracor in writing, or
via mutually acceptable electronic media, on an ongoing basis copies or
reproductions of all Improvements that are reasonably necessary to
research, develop, register, manufacture, market, use or sell Product.
Such Improvements shall be automatically deemed to be within the scope of
the licenses granted herein without payment of any additional
compensation. Sepracor shall have the right to use for all purposes in
connection with Regulatory Approval or any regulatory application for
Product in the Territory all RPR Know-How and other information disclosed
pursuant to this Section and under this Agreement. Upon Sepracor's
request, RPR shall provide reasonable technical assistance to enable
Sepracor to utilize RPR Know-How to obtain Regulatory Approval of
Products, and from time to time at Sepracor's reasonable request, RPR
shall use good faith reasonable efforts to assist Sepracor in providing
responses to questions that may be raised by regulatory authorities in
connection with Sepracor's applications for Regulatory Approval of
Products. Sepracor shall be solely responsible for obtaining all
Regulatory Approvals related to the Product.
5.4 RPR shall use good faith reasonable efforts to cooperate with Sepracor or
its counsel in connection with prosecution of RPR Applications. The
parties acknowledge that assignment of the RPR Application to Sepracor
leaves Sepracor as the only real party in interest in the Interference.
Sepracor shall notify the PTO Administrative Patent Judge assigned to the
Interference of the assignment no later than ten (10) days after the
Effective Date of this Agreement, and shall copy RPR interference counsel
at Finnegan, Henderson, Farabow, Garrett & Dunner on this notification.
Sepracor shall make a good faith determination of priority of invention
and of any other issues that need to be determined relating to the RPR
Application and Sepracor Patent involved in the Interference.
9
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
RPR shall use good faith reasonable efforts to cooperate with Sepracor in
connection with Sepracor's determination(s), including providing
information, documents, or other materials RPR or its Affiliates or
counsel have in its possession that is requested by Sepracor and agreed in
good faith by RPR and Sepracor or its counselto be reasonably necessary to
Sepracor's good faith determination(s). In addition, at Sepracor's or its
counsel's request, RPR shall execute documents reasonably necessary to
Sepracor's good faith determination(s) or prosecution of RPR Applications,
provided, however, that RPR may refuse to execute such documents if RPR
makes a good faith reasonable determination that any such document is
factually or legally incorrect.
5.5 With regard to any cooperation or assistance RPR provides to Sepracor
under Articles 5 and 6, the following shall apply: (1) RPR shall provide a
cumulative total of eighty (80) hours of such cooperation or assistance
free of charge, and (2) thereafter, Sepracor shall reimburse RPR for
reasonable fully allocated costs and expenses incurred by RPR in providing
such cooperation or assistance after receipt of a detailed written invoice
from RPR for such costs and expenses.
ARTICLE 6 - INFRINGEMENT
Sepracor shall have the sole right but not the obligation to enforce at
its expense the RPR Applications. In any suit or dispute involving
infringement of the RPR Applications, or any litigation necessary to
enforce or defend the RPR Applications, the parties shall use good faith
reasonable efforts to cooperate, and upon the request and at the expense
of Sepracor, RPR shall make available to Sepracor at reasonable times and
under appropriate conditions company files that pertain to the RPR
Application or the invention it claims, excluding any materials that are
privileged under the attorney-client privilege or the work-product
doctrine, and RPR employees having personal knowledge concerning the RPR
Application or the invention it claims, and information concerning the
last known address of former RPR employees having personal knowledge
concerning the RPR Application or the invention it claims. Any recovery or
damages derived from enforcement of any RPR Application shall be used to
first reimburse Sepracor for its documented expenses and costs relating to
such enforcement. Thereafter, RPR shall receive the lesser of (a) an
amount equal to [**] of the net sales of Product by the infringing party,
or (b) [**] of the compensatory damages. Any punitive damages, exemplary
damages, or other enhanced damages shall be retained solely by Sepracor.
10
ARTICLE 7 - CONFIDENTIALITY
7.1 During the term of this Agreement, and for a period of five (5) years
thereafter, each party hereto will maintain in confidence all Confidential
Information disclosed by the other party hereto. Neither party shall use,
disclose or grant use of such Confidential Information except as permitted
under this Agreement. To the extent that disclosure is authorized by this
Agreement, the disclosing party shall obtain prior agreement from its
employees, agents, consultants, Affiliates, Licensees or clinical
investigators to whom disclosure is to be made to hold in confidence and
not make use of such information for any purpose other than those
permitted by this Agreement. Each party shall use at least the same
standard of care as it uses to protect its own Confidential Information to
ensure that such employees, agents, consultants and clinical investigators
do not disclose or make any unauthorized use of such Confidential
Information. Each party shall promptly notify the other upon discovery of
any unauthorized use or disclosure of the Confidential Information. The
obligations of confidentiality set forth in this Section 7.1 shall not
apply when and to the extent that Confidential Information:
7.1.1 was already known to the receiving party, other than under an
obligation of confidentiality, at the time of disclosure by the
other party as demonstrated by written documents;
7.1.2 was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the other party;
7.1.3 becomes generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act
or omission of the receiving party in breach of this Agreement;
7.1.4 was disclosed to the receiving party, other than under an
obligation of confidentiality, by a Third Party who had no
obligation to the other party not to disclose such information;
7.1.5 can be demonstrated to have been independently developed by the
receiving party without reference to the disclosure by the other
party; or
7.1.6 is required to be disclosed by the receiving party to regulatory
authorities in connection with registration, marketing,
distribution, use, or sale of Product.
7.2 The material financial terms of the Agreement shall be considered the
Confidential Information of both parties.
7.3 Any other provision of this Agreement notwithstanding, each party may
disclose the Confidential Information to the extent such disclosure is
reasonably necessary in filing or prosecuting patent applications,
prosecuting or defending litigation or complying with
11
applicable governmental regulations. In addition, either party may
disclose such Confidential Information to its Affiliates, and Sepracor may
disclose such Confidential Information to Licensees; provided, however, in
connection with any such disclosure the disclosing party shall use
diligent efforts to secure confidential treatment of such information.
7.4 The parties shall undertake to ensure that all their employees who have
access to Confidential Information of the other party are under
obligations of confidentiality consistent with those provided in Section
7.1.
7.5 To the extent legally required, the parties agree to comply with the
requirements of 35 U.S.C.ss.135(c) relating to submission of agreements
between the parties to the U.S. Patent and Trademark Office.
ARTICLE 8 - TERM
This Agreement will commence as of the Effective Date and, unless sooner
terminated as provided hereunder, shall terminate on the expiration of the
royalty obligations of Article 3, after which time Sepracor will have a
fully paid-up, royalty-free and irrevocable exclusive license under RPR
Know-How and Improvements to develop, have developed, make, have made,
use, market, sell, offer for sale, have sold and distribute Product in the
Territory. Notwithstanding the foregoing, if each and every milestone
payment in Article 3 should fail to come due within ten (10) years from
the Effective Date, or if Sepracor breaches its obligations under Section
2.4, then this Agreement shall terminate ten (10) years from the Effective
Date, or thirty (30) days after RPR gives notice to Sepracor of such
breach, as applicable. Upon any such early termination of this Agreement,
all rights to RPR Know-How and Improvements licensed hereunder to Sepracor
shall revert to RPR, and Sepracor and its Affiliates and Licensees shall
make no further use of the same.
ARTICLE 9 - BREACH AND TERMINATION
In the event Sepracor or RPR are in material breach of any of the
respective obligations and conditions contained in this Agreement, the
other party shall be entitled to give the party in breach notice requiring
it to cure such material breach. If such material breach is not cured
within ninety (90) days after receipt of such notice, the notifying party
may seek a determination of damages for the breach from the breaching
party. Nothing herein shall prevent either party hereto from exercising
such party's right to obtain specific performance or temporary or
permanent injunctive relief or other equitable relief.
12
ARTICLE 10 - REPRESENTATIONS, WARRANTIES AND COVENANTS
10.1 RPR represents and warrants to Sepracor that:
10.1.1 The execution, delivery and performance of this Agreement by RPR
does not conflict with any agreement, instrument or understanding,
oral or written, to which it is a party or by which it may be
bound, and to the best of its knowledge, does not violate any
material law or regulation of any court, governmental body or
administrative or other agency having authority over it;
10.1.2 RPR is not currently a party to, and during the term of this
Agreement will not enter into, any agreements, oral or written,
that are inconsistent with its obligations under this Agreement;
10.1.3 RPR is duly organized and validly existing under the laws of the
state of its incorporation and has full legal power and authority
to enter into this Agreement;
10.1.4 RPR is not subject to any order, decree or injunction by a court
of competent jurisdiction which prevents or materially delays the
consummation of the transactions contemplated by this Agreement;
10.1.5 As of the Effective Date, RPR's right, title and interest in the
RPR Application or RPR Know-How as they relate to Zopiclone
Technology or Product in the Territory are not assigned,
transferred, or conveyed to a Third Party or otherwise encumbered
by a Third Party;
10.1.6 RPR is the sole and exclusive owner of the RPR Application and the
sole and exclusive owner or licensee of the RPR Know-How, all of
which, to the best of RPR's knowledge, are free and clear of any
liens, charges and encumbrances, and, except for RPR's Affiliates,
no other person, corporate or other private entity, or
governmental entity or subdivision thereof has, or shall have, any
claim of control with respect to the RPR Application and the RPR
Know-How as they relate to Zopiclone Technology or Product in the
Territory;
10.1.7 In the Territory, there are no claims, judgments or settlements
against or owed by RPR pending or, to the knowledge of RPR,
threatened, with respect to the RPR Application and the RPR
Know-How as they relate to Zopiclone Technology or Product except
for the Interference;
10.1.8 To the best of RPR's knowledge, there is no RPR Know-How not
disclosed to Sepracor prior to the date of execution hereof that
will substantially adversely affect approval of an NDA for Product
or cause Sepracor to conduct carcinogenicity trials or a one-year
safety study in humans, or to obtain chronic
13
exposure safety data in humans in order to effect registration of
Product in the United States;
10.1.9 The RPR Know-How disclosed to Sepracor prior to the date of
execution hereof is accurate and not contradicted by other RPR
Know-How;
10.1.10 To the best of RPR's knowledge, the development, manufacture, use,
distribution, marketing, promotion and sale of Product in the
Territory do not interfere or infringe on any intellectual
property rights owned or possessed by any Third Party; and
10.1.11 To the best of RPR's knowledge there are no Third Party pending
patent applications which, if issued, may cover the development,
manufacture, use or sale of Product.
10.2 Sepracor represents and warrants to RPR that:
10.2.1 The execution, delivery and performance of this Agreement by
Sepracor does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which
it may be bound, and to the best of its knowledge, does not
violate any material law or regulation of any court, governmental
body or administrative or other agency having authority over it;
10.2.2 Sepracor is not currently a party to, and during the term of this
Agreement will not enter into, any agreements, oral or written,
that are inconsistent with its obligations under this Agreement;
and
10.2.3 Sepracor is duly organized and validly existing under the laws of
the state of its incorporation and has full legal power and
authority to enter into this Agreement;
10.2.4 Sepracor is not subject to any order, decree or injunction by a
court of competent jurisdiction which prevents or materially
delays the consummation of the transactions contemplated by this
Agreement; and
10.2.5 To the best of Sepracor's knowledge, as of the Effective Date,
there are no patent rights of a Third Party that Sepracor is
required to license in order to manufacture, use or sell a Product
in the Territory.
10.3 Subject to Section 2.7, during the term of this Agreement, RPR convenants
that neither RPR nor any of its Affiliates will develop, use, market,
promote, sell or distribute (or agree with any third party to do any of
the foregoing) in the Territory any product containing Compound, the
racemate or the other enantiomer thereof, as an active ingredient.
14
10.4 THE LIMITED WARRANTIES CONTAINED IN THIS ARTICLE ARE THE SOLE WARRANTIES
GIVEN BY THE PARTIES AND ARE MADE EXPRESSLY IN LIEU OF AND EXCLUDE ANY
IMPLIED WARRANTIES INCLUDING WARRANTIES OF MERCHANTABILITY AND FITNESS FOR
A PARTICULAR PURPOSE, AND ALL OTHER EXPRESS OR IMPLIED REPRESENTATIONS AND
WARRANTIES PROVIDED BY COMMON LAW, STATUTE OR OTHERWISE ARE HEREBY
DISCLAIMED BY BOTH PARTIES.
ARTICLE 11 - ADVERSE EVENTS
Following the Effective Date, Sepracor shall be solely responsible for
complying with all legal and/or regulatory obligations in the Territory
regarding the reporting of adverse events related to Product. Each of RPR
and Sepracor shall report to the other potentially serious alleged adverse
drug experiences with respect to the Product of which it becomes aware
promptly and in no event later than five (5) days after initial receipt of
the information by such party. Each such report shall identify lot numbers
and customers affected, if known. Each of RPR and Sepracor will report to
the other party summaries of other adverse drug experiences with respect
to Product of which it becomes aware every twelve (12) months. The terms
of this Article 11 will survive the expiration or sooner termination of
this Agreement.
ARTICLE 12 - INDEMNIFICATION
12.1 Except as otherwise provided to the contrary in this Agreement, Sepracor
agrees to defend, indemnify, and hold harmless RPR, its successors and
assigns, and its officers, directors, employees, stockholders, agents,
Affiliates and any person who controls any of such persons (an
"Indemnified RPR Party") at Sepracor's cost and expense (including
reasonable attorneys' fees) from and against any and all liabilities,
claims, demands, judgments, losses, costs, damages, fees or expenses
whatsoever (collectively, "Liability") that such Indemnified RPR Party
may sustain, suffer or incur arising out of or in connection with the
manufacture, commercialization, marketing, sale or use of any Product in
the Territory, including, but not limited to, any actual or alleged
injury, damage, death or other consequence occurring to any person as a
result, directly or indirectly, of the possession, use or consumption of
any Product, whether claimed by reason of breach of warranty, negligence,
product defect or otherwise, and regardless of the form in which any such
claim is made. Notwithstanding the foregoing, Sepracor shall have no
obligation under this Agreement to indemnify, defend or hold harmless any
Indemnified RPR Party with respect to any Liability which result from
willful misconduct or negligent acts or omissions of RPR, its Affiliates,
or any of their respective employees, officers, directors or agents.
15
12.2 Except as otherwise provided to the contrary in this Agreement, RPR shall
defend, indemnify and hold harmless Sepracor, its successors and assigns,
and its officers, directors, employees, stockholders, agents, Affiliates
and any person who controls any of such persons (an "Indemnified Sepracor
Party") at RPR's cost and expense (including reasonable attorneys' fees
incurred by such Indemnified Sepracor Party in connection therewith) from
and against any and all liabilities, claims, demands, judgments, losses,
costs, damages, fees, or expenses whatsoever (collectively, "Liability")
that such Indemnified Sepracor Party may sustain, suffer or incur to the
extent that such Damages are attributed to any breach of any
representation, warranty, covenant or agreement of RPR contained in this
Agreement. Notwithstanding the foregoing, RPR shall have no obligation
under this Agreement to indemnify, defend or hold harmless any Indemnified
Sepracor Party with respect to any Liability which results from willful
misconduct or negligent acts or omissions of Sepracor, its Affiliates, or
any of their respective employees, officers, directors or agents.
12.3 Each party agrees to promptly give the other party notice of any claim for
which indemnification might be sought. Failure of an indemnified party to
provide notice of a claim to the indemnifying party shall affect the
indemnified party's right to indemnification only to the extent that such
failure has a material adverse effect on the indemnifying party's ability
to defend or the nature or the amount of the Liability. The indemnifying
party shall have the right to assume the defense of any suit or claim
related to the Liability if it has assumed responsibility for the suit or
claim in writing; however, if in the reasonable judgment of the
indemnified party, such suit or claim involves an issue or matter which
could have a materially adverse effect on the business operations or
assets of the indemnified party, the indemnified party may waive its
rights to indemnity under this Agreement and control the defense or
settlement thereof, but in no event shall any such waiver be construed as
a waiver of any indemnification rights such party may have at law or in
equity. If the indemnifying party defends the suit or claim, the
indemnified party may participate in (but not control) the defense thereof
at its sole cost and expense.
12.4 Neither party may settle a claim or action related to a Liability without
the consent of the other party, if such settlement would impose any
monetary obligation on the other party or require the other party to
submit to an injunction or otherwise limit the other party's rights under
this Agreement; provided that such consent shall not unreasonably be
withheld or delayed.
12.5 With respect to any claim by one party against the other arising out of
this Agreement, the parties expressly agree that the liability of such
party to the other party shall be limited under this Agreement or
otherwise at law or equity to direct damages only and in no event shall a
party be liable for, punitive, exemplary or consequential damages.
16
ARTICLE 13 - CHOICE OF LAW
The construction, validity and performance of this Agreement shall be
governed in all respects by the laws of the State of Delaware, without
giving effect to principles of conflict of laws.
ARTICLE 14 - FORCE MAJEURE
No failure or omission by the parties hereto in the performance of any
obligation of this Agreement shall be deemed a breach of this Agreement
nor create any liability if the same shall arise from any cause or causes
beyond the control of the parties, including but not limited to the
following which, for the purposes of this Agreement, shall be regarded as
beyond the control of the party in question; act of God, acts or omissions
of any government or any rules, regulations or orders of any governmental
authority or any officer, department, agency or instrument thereof; fire,
storm, flood, earthquake, accident, acts of the public enemy, war,
rebellion, insurrection, riot, invasion, strikes or lockouts.
ARTICLE 15 - NOTICES
Any notice required or permitted to be given under this Agreement shall be
mailed by registered or certified air mail, postage prepaid, addressed to
the party to be notified at its address stated below, or at such other
address as may hereafter be furnished in writing to the notifying party or
by telefax to the numbers set forth below or to such changed telefax
numbers as may thereafter be furnished.
If to RPR: ▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇, Inc.
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇,
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: General Counsel
Telefax: (▇▇▇) ▇▇▇-▇▇▇▇
If to Sepracor:
Sepracor Inc.
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attn: Chief Executive Officer
Telefax: (▇▇▇) ▇▇▇-▇▇▇▇
Any notice sent under this Article shall be deemed to have been received
on the date which is (i) five (5) Business Days after being mailed in the
case of a notice mailed by
17
registered or certified mail, postage prepaid; and (ii) one (1) Business
Day after being transmitted in the case of a notice transmitted via
telefax.
18
ARTICLE 16 - WAIVER
Any term or provision of this Agreement may be waived at any time by the
party entitled to the benefit thereof by a written instrument duly
executed by such party. The failure of any party at any time or times to
require performance of any provision hereof shall in no manner affect the
right of such party at a later time to enforce the same or any other
provision of this Agreement. No waiver of any condition or of the breach
of any provision of this Agreement in one or more instances shall operate
or be construed as a waiver of any other condition or subsequent breach.
ARTICLE 17 - ENTIRE AGREEMENT
This Agreement constitutes the entire agreement between the parties hereto
concerning the subject matter hereof and any representation, promise or
condition in connection therewith, not incorporated herein, shall not be
binding upon either party. This Agreement, including without limitation
the Schedules attached hereto, are intended to define the full extent of
the legally enforceable undertakings of the parties hereto, and no promise
or representation, written or oral, which is not set forth explicitly
herein is intended by either party to be legally binding. This Agreement
may only be modified, amended or supplemented by an instrument in writing
executed by RPR and Sepracor.
ARTICLE 18 - ASSIGNMENT
18.1 Except as otherwise provided herein, this Agreement is not assignable
either in whole or in part without the prior written consent of the other
party; provided, however, that either party may assign this Agreement to
any of its Affiliates or to any successor by merger or sale of
substantially of all of its business unit to which the Agreement relates.
18.2 This Agreement will be binding upon successors and permitted assigns of
the parties and the name of a party appearing herein will be deemed to
include the name of such party's successor's and permitted assigns to the
extent necessary to carry out the intent of this section.
ARTICLE 19 - TITLES
It is agreed that the marginal headings appearing at the beginning of the
numbered Articles hereof have been inserted for convenience only and do
not constitute any part of this Agreement.
19
ARTICLE 20 - PUBLICITY
Except as otherwise specifically provided to the contrary herein, neither
party will issue any press release, publication, presentation, or any
other public announcement relating to this Agreement without obtaining the
other party's prior written approval, which approval will not be
unreasonably withheld. Sepracor shall be permitted to issue a press
release concerning this Agreement, which is agreed to by RPR and Sepracor,
and such agreement shall not be unreasonably withheld or delayed. The
parties further agree to use reasonable efforts to keep terms of this
Agreement confidential, including with respect to submissions that
Sepracor may be required to make to regulatory authorities, to the extent
that such protection may be available through said regulatory authorities.
Notwithstanding any of the foregoing, each party may use the substance of
previously approved public announcements and the substance of other public
announcements of the other party concerning the subject matter of this
Agreement without prior notice.
ARTICLE 21 - UNENFORCEABLE PROVISIONS
The provisions of this Agreement shall be deemed severable and the
invalidity or unenforceability of any provision shall not affect the
validity or enforceability of the other provisions hereof. If any
provision of this Agreement, or the application thereof to any person or
entity or any circumstance, is invalid or unenforceable, (i) a suitable
and equitable provision shall be substituted therefore in order to carry
out, so far as may be valid and enforceable, the intent and purpose of
such invalid and unenforceable provision and (ii) the remainder of this
Agreement and the application of such provision to other persons, entities
or circumstances shall not be affected by such invalidity or
unenforceability, nor shall such invalidity or unenforceability affect
such provision, or the application thereof, in any other jurisdiction.
ARTICLE 22 - CONSTRUCTION
As used in this Agreement, singular includes the plural and plural
includes the singular, wherever so required by fact or context.
ARTICLE 23 - OWNERSHIP
23.1 Nothing in this Agreement shall be construed as conveying or transferring
patent or technology rights of any kind owned by Sepracor to RPR.
23.2 All business decisions, including, but not limited to, decisions
concerning pricing, reimbursement, package design, sales and promotional
activities for Product, and the decision to launch or continue to market
Product in the Territory, shall be within the sole discretion of Sepracor.
20
ARTICLE 24 - INDEPENDENT CONTRACTORS
In making and performing this Agreement, the parties are acting and shall
act as independent contractors. Nothing in this Agreement shall be deemed
to create an agency, joint venture or partnership relationship between the
parties hereto.
ARTICLE 25 - EXECUTION
This Agreement shall be executed in one or more counterparts, each of
which shall for all purposes be deemed an original.
21
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their respective duly authorized officers or representatives as of
the day and year first above written.
SEPRACOR INC.
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
---------------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------------
Title: Chief Executive Officer
------------------------------
▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇
By: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
---------------------------------
Name: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
------------------------------
Title: Director, ▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇.▇.
------------------------------
Senior Vice President and Chief Financial
Officer, ▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇, Inc.,
authorized signer for
▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇.▇.
22
SCHEDULE 1.15
RPR PATENT APPLICATIONS
RPR PATENT APPLICATIONS
[**]
SCHEDULE 2.1
FORM OF ASSIGNMENT
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
ASSIGNMENT
WHEREAS, ▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇ ("RPR"), a French corporation having a place of
business at ▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇▇▇-▇▇▇▇, ▇-▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇, is the sole owner
of U.S. Patent Application Serial No. [**] (the "[**] Application"), and United
States patent applications related thereto; and
WHEREAS, Sepracor Inc. ("Sepracor"), a Delaware corporation having a place of
business at ▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, is desirous of
obtaining RPR's entire right, title, and interest in, to, and under the [**]
Application, and United States patent applications related thereto, and RPR
desires to assign to Sepracor its entire right, title and interest in the same.
NOW, THEREFORE, in consideration of the premises, one dollar, and other good and
valuable consideration to RPR, the receipt and sufficiency of which is hereby
acknowledged, RPR hereby assigns to Sepracor its entire right, title and
interest in, to, and under the [**] Application and the related United States
patent applications listed in Attachment A (collectively, the "RPR
Applications", all of which are hereby incorporated by reference as if fully set
forth herein) including, but not limited to, any additions, divisions,
continuations, continuations-in-part, reissues, re-examinations, substitutions,
extensions, patent term extensions and renewals of the RPR Applications, and
patents issuing therefrom, in each case, as fully and entirely as the same would
have been held and enjoyed by RPR if this assignment had not been made.
RPR also authorizes and requests that the Commissioner of Patents and Trademarks
of the United States, whose duty it is to issue patents or other evidence or
forms of industrial property protection on applications as aforesaid, to issue
the same to Sepracor in accordance with the terms of this instrument.
IN WITNESS WHEREOF, the undersigned duly authorized representative of RPR
has affixed his signature.
▇▇▇▇▇-▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇
By: _____________________________ Date: ______________________
Name:
Title:
State of )
) SS.:
County of )
On this _____ day of _________, 1999, before me, a Notary Public in and
for the State and County aforesaid, personally appeared ___________, to me known
and known to me to be the person of that name, who signed and sealed the
foregoing instrument, and he acknowledged the same to be his free act and deed.
_________________________,
Notary Public.
2
Attachment A
[**]
